Why the study?
Hepatitis E is not easily distinguished clinically from other acute viral hepatitides, creating a need for diagnostic assays to detect and prevent interspecies transmission.
Does a nanobody-based competitive ELISA accurately detect antibodies against Hepatitis E Virus compared to a commercial kit?
Population
Reference panel of human (n = 86) and swine sera (n = 116), plus wild boar, deer, and mice
Comparison
Competitive nanobody-based ELISA vs a commercial kit
Design
Diagnostic validation study
Authors
Loading...
Nanobodies may advance HEV diagnostics in susceptible groups; leaves open clinical validation for transmission prevention.
Does a nanobody-based competitive ELISA accurately detect antibodies against Hepatitis E Virus compared to a commercial kit?
A novel nanobody-based competitive ELISA shows high sensitivity and specificity for detecting anti-HEV antibodies across multiple species.
Arce et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: